Osprey Medical announced today that Dan Mans has joined the Company’s executive team as Vice President of Clinical and Regulatory Affairs.Dan has more than 20 years of experience in the medical device industry and has held senior executive level positions in both publicly held and private companies.
Prior to joining Osprey Medical, Dan held positions with Voyageur Medical, American Medical Systems, Medtronic, and several successful start-up companies.Over his career, he has managed the clinical and regulatory functions for a variety of products in electrophysiology, cardiac surgery, spinal orthopedics, urology and gynecology. He has testified twice before FDA advisory panels, both times gaining unanimous recommendation for approval for first-of-a-kind PMA devices. He has conducted clinical research and garnered product approvals in the US, Canada, Europe and Asia.
Mike McCormick, the Company’s President and CEO, commented, “Attracting a person of Dan’s caliber, experience level, and reputation is an important accomplishment for Osprey, allowing us to accelerate our clinical trial activity in support of securing regulatory clearance for our contrast induced nephropathy therapy. We are delighted to have Dan join our management team.”
About Contrast Induced Nephropathy (CIN)
Contrast induced nephropathy (CIN) is an acute, hospital acquired kidney injury caused by contrast media (dye) used during percutaneous coronary procedures such as angioplasty and stenting. Patients at high risk for CIN have pre-existing chronic kidney disease. Contrast media can further damage their kidneys leading to longer hospital stays, serious complications, or even death.
About Osprey Medical, Inc.
Osprey Medical is a privately held company located in Eden Prairie, Minnesota. The Company is dedicated to the treatment and prevention of ailments originating from the inter-related functioning of the heart and kidneys with a primary focus on CIN. The Company’s CINCOR™ Contrast Removal System is a catheter based system that is designed to remove contrast media directly from the heart (coronary sinus) during an interventional coronary procedure before it can enter the kidneys and cause further damage.